{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:03Z","timestamp":1794047463569,"version":"4.8.0"},"reference-count":43,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Mitapivat, a pyruvate kinase activator, shows great potential as a sickle cell disease (SCD)-modifying therapy. The safety and efficacy of mitapivat as a long-term maintenance therapy are currently being evaluated in two open-label studies. Here we applied a comprehensive multi-omics approach to investigate the impact of activating pyruvate kinase on red blood cells (RBC) from 15 SCD patients. HbSS patients were enrolled in one of the open-label, extended studies (NCT04610866). Leukodepleted RBC obtained from fresh whole blood at baseline, prior to drug initiation, and at longitudinal timepoints over the course of the study were processed for multi-omics through a stepwise extraction of metabolites, lipids and proteins. Mitapivat therapy had significant effects on the metabolome, lipidome and proteome of SCD RBC. Mitapivat decreased 2,3-diphosphoglycerate levels, increased adenosine triphosphate levels, and improved hematologic and sickling parameters in patients with SCD. Agreement between omics measurements and clinical measurements confirmed the specificity of mitapivat on targeting late glycolysis, with glycolytic metabolites ranking as the top correlates to parameters of hemoglobin S oxygen affinity (p50) and sickling kinetics (t50) during treatment. Mitapivat markedly reduced levels of proteins of mitochondrial origin within 2 weeks of initiation of treatment, with minimal changes in reticulocyte counts. In the first 6 months of treatment there were also transient elevations of lysophosphatidylcholines and oxylipins with depletion of free fatty acids, suggestive of an effect on membrane lipid remodeling. Multi-omics analysis of RBC identified benefits for glycolysis, as well as activation of the Lands cycle.<\/jats:p>","DOI":"10.3324\/haematol.2023.284831","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T02:11:07Z","timestamp":1709777467000},"page":"2639-2652","source":"Crossref","is-referenced-by-count":10,"title":["Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease"],"prefix":"10.3324","volume":"109","author":[{"given":"Angelo","family":"D\u2019Alessandro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Lundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"Dunkelberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Cellmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Worth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spurthi","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Huston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Grier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Dzieciatkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swee Lay","family":"Thein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"64830","doi-asserted-by":"crossref","unstructured":"D\u2019Alessandro A, Earley EJ, Nemkov T. Genetic polymorphisms and expression of Rhesus blood group RHCE are associated with 2,3-bisphosphoglycerate in humans at high altitude. Proc Natl Acad Sci U S A. 2024; 121(1):e2315930120.","DOI":"10.1073\/pnas.2315930120"},{"key":"64831","doi-asserted-by":"crossref","unstructured":"Sunshine HR, Hofrichter J, Ferrone FA, Eaton WA. Oxygen binding by sickle cell hemoglobin polymers. J Mol Biol. 1982; 158(2):251-273.","DOI":"10.1016\/0022-2836(82)90432-6"},{"key":"64832","doi-asserted-by":"crossref","unstructured":"Hofrichter J, Ross PD, Eaton WA. Supersaturation in sickle cell hemoglobin solutions. Proc Natl Acad Sci U S A. 1976; 73(9):3035-3039.","DOI":"10.1073\/pnas.73.9.3035"},{"key":"64833","doi-asserted-by":"crossref","unstructured":"Goldberg MA, Husson MA, Bunn HF. Participation of hemoglobins A and F in polymerization of sickle hemoglobin. J Biol Chem. 1977; 252(10):3414-3421.","DOI":"10.1016\/S0021-9258(17)40407-8"},{"key":"64834","unstructured":"Nemkov T, Stephenson D, Earley E. Biological and genetic determinants of red blood cell glycolysis. bioRxiv. 2023."},{"key":"64835","doi-asserted-by":"crossref","unstructured":"Adebiyi MG, Manalo JM, Xia Y. Metabolomic and molecular insights into sickle cell disease and innovative therapies. Blood Adv. 2019; 3(8):1347-1355.","DOI":"10.1182\/bloodadvances.2018030619"},{"key":"64836","doi-asserted-by":"crossref","unstructured":"Xu JZ, Conrey A, Frey I. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Blood. 2022; 140(19):2053-2062.","DOI":"10.1182\/blood.2022015403"},{"key":"64837","doi-asserted-by":"crossref","unstructured":"van Dijk MJ, Rab MAE, van Oirschot BA. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study. Am J Hematol. 2022; 97(7):E226-E229.","DOI":"10.1002\/ajh.26554"},{"key":"64838","doi-asserted-by":"crossref","unstructured":"Sun K, D\u2019Alessandro A, Ahmed MH. Structural and functional insight of sphingosine 1-phosphate-mediated pathogenic metabolic reprogramming in sickle cell disease. Sci Rep. 2017; 7(1):15281.","DOI":"10.1038\/s41598-017-13667-8"},{"key":"64839","doi-asserted-by":"crossref","unstructured":"Darghouth D, Koehl B, Madalinski G. Pathophysiology of sickle cell disease is mirrored by the red blood cell metabolome. Blood. 2011; 117(6):e57-e66.","DOI":"10.1182\/blood-2010-07-299636"},{"key":"64840","doi-asserted-by":"crossref","unstructured":"D\u2019Alessandro A, Nouraie SM, Zhang Y. In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction. Am J Hematol. 2023; 98(7):1017-1028.","DOI":"10.1002\/ajh.26923"},{"key":"64841","doi-asserted-by":"crossref","unstructured":"World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-2194.","DOI":"10.1001\/jama.2013.281053"},{"key":"64842","doi-asserted-by":"crossref","unstructured":"Conrey A, Frey I, Asomaning N. Long-term safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with sickle cell disease: extension of a phase 1 dose escalation study. Blood. 2023; 142(Suppl 1):273.","DOI":"10.1182\/blood-2023-180165"},{"key":"64843","doi-asserted-by":"crossref","unstructured":"Beutler E, Blume KG, Kaplan JC, L\u00f6hr GW, Ramot B, Valentine WN. International Committee for Standardization in Haematology: recommended methods for red-cell enzyme analysis. Br J Haematol. 1977; 35(2):331-340.","DOI":"10.1111\/j.1365-2141.1977.tb00589.x"},{"key":"64844","unstructured":"Beutler E. Red Cell Metabolism: A Manual of Biochemical Methods. 3rd edition. 1984."},{"key":"64845","doi-asserted-by":"crossref","unstructured":"Metaferia B, Cellmer T, Dunkelberger EB. Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease. Proc Natl Acad Sci U S A. 2022; 119(40):e2210779119.","DOI":"10.1073\/pnas.2210779119"},{"key":"64846","doi-asserted-by":"crossref","unstructured":"Nemkov T, Reisz JA, Gehrke S, Hansen KC, D\u2019Alessandro A. High-throughput metabolomics: isocratic and gradient mass spectrometry-based methods. Methods Mol Biol. 2019; 1978:13-26.","DOI":"10.1007\/978-1-4939-9236-2_2"},{"key":"64847","doi-asserted-by":"crossref","unstructured":"Reisz JA, Zheng C, D\u2019Alessandro A, Nemkov T. Untargeted and semi-targeted lipid analysis of biological samples using mass spectrometry-based metabolomics. Methods Mol Biol. 2019; 1978:121-135.","DOI":"10.1007\/978-1-4939-9236-2_8"},{"key":"64848","doi-asserted-by":"crossref","unstructured":"Thomas T, Stefanoni D, Dzieciatkowska M. Evidence of structural protein damage and membrane lipid remodeling in red blood cells from COVID-19 patients. J Proteome Res. 2020; 19(11):4455-4469.","DOI":"10.1021\/acs.jproteome.0c00606"},{"key":"64849","doi-asserted-by":"crossref","unstructured":"Song A, Wen AQ, Wen YE. p97 dysfunction underlies a loss of quality control of damaged membrane proteins and promotes oxidative stress and sickling in sickle cell disease. FASEB J. 2022; 36(5):e22246.","DOI":"10.1096\/fj.202101500RR"},{"key":"64850","doi-asserted-by":"crossref","unstructured":"Wu H, Bogdanov M, Zhang Y. Hypoxia-mediated impaired erythrocyte Lands\u2019 cycle is pathogenic for sickle cell disease. Sci Rep. 2016; 6:29637.","DOI":"10.1038\/srep29637"},{"key":"64851","doi-asserted-by":"crossref","unstructured":"Zhang Y, Dai Y, Wen J. Detrimental effects of adenosine signaling in sickle cell disease. Nat Med. 2011; 17(1):79-86.","DOI":"10.1038\/nm.2280"},{"key":"64852","doi-asserted-by":"crossref","unstructured":"Demb\u00e9l\u00e9 KC, Mintz T, Veyrat-Durebex C. Metabolomic profiling of plasma and erythrocytes in sickle mice points to altered nociceptive pathways. Cells. 2020; 9(6):1334.","DOI":"10.3390\/cells9061334"},{"key":"64853","doi-asserted-by":"crossref","unstructured":"Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest. 2017; 127(3):750-760.","DOI":"10.1172\/JCI89741"},{"key":"64854","doi-asserted-by":"crossref","unstructured":"Ribeiro PR, Teixeira RdS, Souza AR. Blood plasma metabolomics of children and adolescents with sickle cell anaemia treated with hydroxycarbamide: a new tool for uncovering biochemical alterations. Br J Haematol. 2021; 192(5):922-931.","DOI":"10.1111\/bjh.17315"},{"key":"64855","doi-asserted-by":"crossref","unstructured":"Cendali FI, Nemkov T, Lisk C. Metabolic correlates to critical speed in murine models of sickle cell disease. Front Physiol. 2023; 14:1151268.","DOI":"10.3389\/fphys.2023.1151268"},{"key":"64856","doi-asserted-by":"crossref","unstructured":"Nemkov T, Skinner S, Diaw M. Plasma levels of acylcarnitines and carboxylic acids correlate with cardiovascular and kidney function in subjects with sickle cell trait. Front Physiol. 2022; 13:916197.","DOI":"10.3389\/fphys.2022.916197"},{"key":"64857","doi-asserted-by":"crossref","unstructured":"D\u2019Alessandro A, Nouraie SM, Zhang Y. Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment. Haematologica. 2023; 108(12):3418-3432.","DOI":"10.3324\/haematol.2023.283288"},{"key":"64858","doi-asserted-by":"crossref","unstructured":"Glenth\u00f8j A, van Beers EJ, Al-Samkari H. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, singlearm, phase 3 trial. Lancet Haematol. 2022; 9(10):e724-e732.","DOI":"10.1016\/S2352-3026(22)00214-9"},{"key":"64859","doi-asserted-by":"crossref","unstructured":"Al-Samkari H, Galact\u00e9ros F, Glenth\u00f8j A. Mitapivat versus placebo for pyruvate kinase deficiency. N Engl J Med. 2022; 386(15):1432-1442.","DOI":"10.1056\/NEJMoa2116634"},{"key":"64860","doi-asserted-by":"crossref","unstructured":"D\u2019Alessandro A, Anastasiadi AT, Tzounakas VL. Red blood cell metabolism in vivo and in vitro. Metabolites. 2023; 13(7):793.","DOI":"10.3390\/metabo13070793"},{"key":"64861","doi-asserted-by":"crossref","unstructured":"van Dijk MJ, van der Veen S, Rab MAE. Untargeted metabolomics on dried blood spots of patients with sickle cell disease treated with the pyruvate kinase activator mitapivat. Blood. 2022; 140(Suppl 1):21-23.","DOI":"10.1182\/blood-2022-155997"},{"key":"64862","doi-asserted-by":"crossref","unstructured":"Bardyn M, Crettaz D, Rappaz B. Phosphoproteomics and morphology of stored human red blood cells treated by protein-tyrosine-phosphatases inhibitor. Blood Adv. 2023; 8(1):1-13.","DOI":"10.1182\/bloodadvances.2023009964"},{"key":"64863","doi-asserted-by":"crossref","unstructured":"Xu P, Chen C, Zhang Y. Erythrocyte transglutaminase-2 combats hypoxia and chronic kidney disease by promoting oxygen delivery and carnitine homeostasis. Cell Metab. 2022; 34(2):299-316.","DOI":"10.1016\/j.cmet.2021.12.019"},{"key":"64864","doi-asserted-by":"crossref","unstructured":"D\u2019Alessandro A, Key A, Amireault P. Genetic regulation of carnitine metabolism controls lipid damage repair mechanisms and hemolytic propensity of human red blood cells during aging in vivo and in vitro. Blood. 2023; 142(Suppl 1):4032.","DOI":"10.1182\/blood-2023-178842"},{"key":"64865","doi-asserted-by":"crossref","unstructured":"Tumburu L, Ghosh-Choudhary S, Seifuddin FT. Circulating mitochondrial DNA is a proinflammatory DAMP in sickle cell disease. Blood. 2021; 137(22):3116-3126.","DOI":"10.1182\/blood.2020009063"},{"key":"64866","doi-asserted-by":"crossref","unstructured":"Moriconi C, Dzieciatkowska M, Roy M. Retention of functional mitochondria in mature red blood cells from patients with sickle cell disease. Br J Haematol. 2022; 198(3):574-586.","DOI":"10.1111\/bjh.18287"},{"key":"64867","unstructured":"Jagadeeswaran R, Lenny H, Vazquez B. The abnormal presence of mitochondria in circulating red blood cells cause an increased oxygen consumption rate, ROS generation and hemolysis in patients with sickle cell disease. Blood. 2017; 130(Suppl 1):2237."},{"key":"64868","doi-asserted-by":"crossref","unstructured":"Tannahill GM, Curtis AM, Adamik J. Succinate is an inflammatory signal that induces IL-1\u03b2 through HIF-1\u03b1. Nature. 2013; 496(7444):238-242.","DOI":"10.1038\/nature11986"},{"key":"64869","doi-asserted-by":"crossref","unstructured":"Zecchini V, Paupe V, Herranz-Montoya I. Fumarate induces vesicular release of mtDNA to drive innate immunity. Nature. 2023; 615(7952):499-506.","DOI":"10.1038\/s41586-023-05770-w"},{"key":"64870","doi-asserted-by":"crossref","unstructured":"Giordano AMS, Luciani M, Gatto F. DNA damage contributes to neurotoxic inflammation in Aicardi-Gouti\u00e8res syndrome astrocytes. J Exp Med. 2022; 219(4):e20211121.","DOI":"10.1084\/jem.20211121"},{"key":"64871","doi-asserted-by":"crossref","unstructured":"Unali G, Crivicich G, Pagani I. Interferon-inducible phospholipids govern IFITM3-dependent endosomal antiviral immunity. EMBO J. 2023; 42(10):e112234.","DOI":"10.15252\/embj.2022112234"},{"key":"64872","doi-asserted-by":"crossref","unstructured":"Nemkov T, Stephenson D, Erickson C. Regulation of kynurenine metabolism by blood donor genetics and biology impacts red cell hemolysis in vitro and in vivo. Blood. 2024; 143(5):456-472.","DOI":"10.1182\/blood.2023022052"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284831\/76729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284831\/77355","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11494\/76729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:56Z","timestamp":1794045956000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284831","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}